EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

Christopher L Mendias, Tariq M Awan

Sports Medicine · 2026-08 · 56 (8) · 1921-1935

DOI: 10.1007/s40279-026-02437-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Sports Medicine, online erschienen am 12.04.2026. Verfasst von Christopher L Mendias und 1 weiteren Autor:innen. Beteiligte Einrichtung: Performance Medicine Institute, 3330 N 2nd St Ste 401, Phoenix, AZ, 85012, USA. cmendias@performancemedinst.com. Hauptthemen laut MEDLINE: Peptides, Athletic Injuries, Athletic Performance, Musculoskeletal System. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 109 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside of regulatory oversight. Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295, FS-344 (follistatin-344), GHK-Cu (glycyl-L-histidyl-L-lysine copper), ipamorelin, MOTS-C (mitochondrial ORF of the 12S rRNA type-c), sermorelin, SS-31 (elamipretide), tesamorelin (Egrifta), Tβ4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment). Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients. This narrative review focuses on the utilization of peptides in sports medicine, and alternative treatments that may be considered. We provide a framework to navigate patient discussions about peptides to better facilitate evidence-based practices for musculoskeletal healing and athletic performance. We also discuss the placebo effect as a mediator of peptide efficacy, and how social media amplifies this effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PeptidesAthletic InjuriesAthletic PerformanceMusculoskeletal SystemPerformance-Enhancing SubstancesHumansAnimalsPeptide Fragments

Substanzen

PeptidesPerformance-Enhancing SubstancesPeptide Fragments

Autor:innen und Institutionen

  • Performance Medicine Institute, 3330 N 2nd St Ste 401, Phoenix, AZ, 85012, USA. cmendias@performancemedinst.com.
  • Performance Medicine Institute, 3330 N 2nd St Ste 401, Phoenix, AZ, 85012, USA.

Zitieren

APA

Mendias, C. L., & Awan, T. M. (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine, 56(8), 1921-1935. https://doi.org/10.1007/s40279-026-02437-0

Vancouver

Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026;56(8):1921-1935. doi:10.1007/s40279-026-02437-0

BibTeX
@article{Mendias2026,
  author = {Mendias, Christopher L and Awan, Tariq M},
  title = {Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance},
  journal = {Sports Medicine},
  year = {2026},
  volume = {56},
  number = {8},
  pages = {1921--1935},
  doi = {10.1007/s40279-026-02437-0}
}
Kostenlos starten →